Naxions Secures RMB 200 Million Series C Funding Led by Sequoia Capital China to Advance Pharma Digitalization
VCBeat (WeChat ID: vcbeat) has learned that Beijing Naxions Co., Ltd. announced the completion of a new round of financing amounting to RMB 200 million. This round was led by Sequoia Capital China, with continued participation from existing investors Matrix Partners China, Zhichun Capital, Morningside Venture Capital, Volcanic Stone Capital, CCV Capital, and FreeS Fund.
Less than six months have passed since Naxions Co.,Ltd.’s previous funding round, marking the company’s third financing within a year. Ruan Wei, the company’s founder, stated that the proceeds from this round will be primarily allocated to business expansion, technological investment, and solution optimization.
Naxions Co., Ltd. is a leading provider of digital pharmaceutical promotion solutions in China. Leveraging globally advanced semantic understanding and deep learning algorithms, the company has independently developed an intelligent business operations platform that integrates into the core business processes of pharmaceutical manufacturers. By streamlining both internal and external drug promotion workflows, Naxions helps pharmaceutical companies enhance operational efficiency while ensuring compliance, thereby improving drug accessibility.
In 2020, Naxions Co., Ltd. maintained a high-speed growth rate of over 500% in its core business, with solutions covering 100 types of pharmaceutical products, more than 200,000 highly active physicians, and achieving contract revenue exceeding RMB 100 million.
Since its establishment, Naxions Co.,Ltd. has focused on providing digital promotion solutions for pharmaceutical companies. For pharmaceutical enterprises, Naxions applies “data analysis/management tools/business consulting + execution” by leveraging leading artificial intelligence technologies. Through more precise online promotion solutions, it is committed to helping pharmaceutical companies transform traditional pharmaceutical promotion models and establish compliant and efficient digital systems. For physicians, Naxions provides high-quality information resources and services to doctors at all levels, helping clinicians access professional information and use professional tools more efficiently and conveniently, thereby improving their diagnostic and treatment capabilities. For patients, Naxions offers a platform for interaction between patients and doctors, facilitating chronic disease management for both parties and enhancing patients’ quality of life.
Currently, China’s pharmaceutical industry is undergoing reform. Continuous healthcare reforms have introduced significant variables and opportunities into the market. Amidst this uncertainty, Naxions Co.,Ltd. has secured a competitive edge through its proprietary technology, aligning with the direction of healthcare reform and gaining deep insights into the needs of pharmaceutical companies and physicians. By leveraging new technologies and tools, the company has substantially enhanced efficiency in the emerging pharmaceutical marketing sector. It connects the vast pharmaceutical promotion and sales market with millions of medical institutions and physicians, shifting pharmaceutical marketing scenarios from traditional offline channels to online platforms, thereby enabling more precise, cost-effective, transparent, and compliant drug promotion. Naxions Co.,Ltd. has also established a dual-drive business model.
Zhai Jia, Managing Director at Sequoia Capital China, stated, “With the continuous rollout of national policies such as ‘Volume-Based Procurement’ and the ‘4+7’ pilot program, the traditional labor-intensive sales model of pharmaceutical companies has faced severe challenges. There is an urgent need for efficient marketing models and services. Digital transformation in pharmaceutical enterprises, particularly innovative drug marketing, will be a major future trend. The Naxions team demonstrates strong resilience and a pragmatic approach, combining internet technology capabilities with extensive experience in the pharmaceutical industry. By integrating big data, building AI-driven information systems, and establishing a comprehensive empowered marketing framework, the company has created an efficient two-way communication mechanism between pharmaceutical companies and physicians. This enables precise matching of value for both parties, rapidly addresses the diverse needs of primary care physicians, and helps improve their diagnostic and treatment capabilities.”
The national government has introduced a tiered diagnosis and treatment policy, aiming to ensure that patients with serious conditions receive care within their county and that 90% of patients are diagnosed and treated at the county level. County-level hospitals in China serve a population of over 900 million, accounting for more than 90% of the nation’s total residents, indicating substantial growth potential in the grassroots healthcare market.
Despite its immense potential, the primary healthcare sector has long been overlooked by multinational pharmaceutical companies due to several key factors: underdeveloped care standards at the grassroots level, high price sensitivity among patients, and the small scale, wide distribution, and remote locations of primary healthcare institutions. However, as healthcare policies increasingly favor the primary care market, penetrating this segment has become a crucial strategy for multinational pharmaceutical firms. Consequently, these companies need to invest more human and financial resources in educating the market about medications used in primary healthcare settings.
In real-world clinical settings, physicians face significant inter-patient variability, leading to highly individualized needs and a diverse range of challenges to address. Pharmaceutical companies and physicians need to establish a bidirectional dialogue mechanism leveraging advanced technologies and platforms. This approach not only enables precise alignment of mutual value but also rapidly meets the diverse needs of primary care physicians. Technology and algorithms are key to solving these problems, as they help physicians gain a comprehensive understanding of medications more efficiently, thereby enhancing their clinical capabilities and improving patient care.
For physicians, the tool provided by Naxions Co., Ltd.—Naxion Academy (Mini Program)—enables them to independently query comprehensive information on prescription drugs, including physicochemical properties, adverse reactions, case studies, and disease-related details such as diagnostic methods, symptoms, treatment modalities, and medication regimens (first-line agents, second-line options, combination therapies, etc.). This meets their daily prescribing needs. Additionally, physicians can engage in professional discussions within the community to enhance their expertise, thereby increasing their stickiness to the platform.
As healthcare and pharmaceutical reforms deepen, the direction of reform is toward higher quality medical services, broader accessibility to healthcare, and more inclusive payment mechanisms. Among these trends, compressing drug distribution channels and curbing artificially inflated drug prices have become unstoppable forces. This policy resolve is evident in recent national initiatives such as the “Two-Invoice System,” consistency evaluation, and volume-based procurement.
Ruan Wei stated, “Although the process has been extremely challenging, the outcome has proven that doing what is right in terms of long-term trends will ultimately demonstrate its value, as long as one perseveres. We believe that medication access can certainly become both inclusive and professional, which represents a major long-term trend in the pharmaceutical distribution sector. Therefore, aligning with the policy direction of making drugs as affordable as possible is simply going with the flow. There are many ways to reduce drug prices, but the most critical factor is the efficiency of value matching. This is especially true in two-sided markets.”
Traditional pharmaceutical sales representatives influence physicians’ prescribing practices through “kickback-driven sales,” a practice that is clearly contrary to current trends. It adds layers to the distribution chain and increases financial outlays, which are ultimately reflected in drug prices and borne by end consumers—namely, patients.
Naxions Co., Ltd. has created a direct channel connecting online pharmaceutical companies with physicians, enhancing the efficiency of value matching.
Ruan Wei also admitted, “The journey was fraught with difficulties, as the existing chain of interests was deeply entrenched. The reason Naxions Co., Ltd. managed to persist until it gained market recognition was primarily due to the impetus provided by healthcare reform policies over the past five years.”
On one hand, policies such as the separation of prescribing and dispensing, the two-invoice system, and volume-based procurement have continuously squeezed gross margins in the pharmaceutical distribution sector, effectively lowered drug prices, and significantly reduced pharmaceutical companies’ revenues and profits. Consequently, within the existing market, pharmaceutical companies require more efficient and cost-effective promotional methods and channels for physician education. Naxions Co., Ltd., with its years of deep industry expertise, has naturally become a preferred choice.
On the other hand, as the tiered diagnosis and treatment policy for patients and physicians begins to show results, the lower-tier markets have become a new battleground for pharmaceutical companies. Faced with this incremental market, characterized by its vastness and fragmentation, it is difficult for any single pharmaceutical company to achieve comprehensive coverage. This presents significant opportunities for business models like that of Naxions Co., Ltd., which serves as a bridge between physicians and pharmaceutical companies.
Furthermore, driven by policies promoting the domestic substitution of pharmaceutical innovations, new drug R&D enterprises are emerging. These companies urgently need to educate the market to secure room for growth, which also presents a new opportunity for Naxions Co., Ltd. to expand its boundaries.
Completing three rounds of financing within a year and gaining recognition from multiple renowned investment institutions, Naxions Co., Ltd. owes its success not only to its first-mover advantage in the market and robust technological reserves but also to its diverse and innovative team, which represents a significant value proposition.
Naxions Co., Ltd.’s executive team comprises leaders from renowned companies both within and outside the industry, forming a true “cross-sector alliance.” The Naxions team is driven by technology, with technical staff accounting for more than half of its workforce. Many of these professionals come from leading internet giants such as Alibaba, JD.com, Baidu, ByteDance, and Meituan. “Energetic, courageous, and innovative” are the most distinctive hallmarks of the Naxions team.
Naxions Co.,Ltd. aspires to become a truly technology- and product-driven company. By continuously innovating, we aim to leverage technology to serve commerce and enhance overall industry efficiency through data and technological advancements amidst the wave of healthcare system reform. We are committed to meeting physicians’ needs for improved diagnostic and treatment capabilities, helping patients lead happier lives, and contributing our share to China’s pharmaceutical reform endeavors.